187 related articles for article (PubMed ID: 11567982)
21. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.
Rennick LJ; de Vries RD; Carsillo TJ; Lemon K; van Amerongen G; Ludlow M; Nguyen DT; Yüksel S; Verburgh RJ; Haddock P; McQuaid S; Duprex WP; de Swart RL
J Virol; 2015 Feb; 89(4):2192-200. PubMed ID: 25473055
[TBL] [Abstract][Full Text] [Related]
22. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
24. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.
Boisgerault N; Guillerme JB; Pouliquen D; Mesel-Lemoine M; Achard C; Combredet C; Fonteneau JF; Tangy F; Grégoire M
Biomed Res Int; 2013; 2013():387362. PubMed ID: 23586034
[TBL] [Abstract][Full Text] [Related]
25. A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.
Nürnberger C; Bodmer BS; Fiedler AH; Gabriel G; Mühlebach MD
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429338
[TBL] [Abstract][Full Text] [Related]
26. Measles virus spread and pathogenesis in genetically modified mice.
Mrkic B; Pavlovic J; Rülicke T; Volpe P; Buchholz CJ; Hourcade D; Atkinson JP; Aguzzi A; Cattaneo R
J Virol; 1998 Sep; 72(9):7420-7. PubMed ID: 9696838
[TBL] [Abstract][Full Text] [Related]
27. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
28. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
30. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
31. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
32. Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System.
Xia M; Wang Y; Xia Y; Zeng J
Curr Microbiol; 2024 Feb; 81(4):93. PubMed ID: 38334775
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
34. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.
Combredet C; Labrousse V; Mollet L; Lorin C; Delebecque F; Hurtrel B; McClure H; Feinberg MB; Brahic M; Tangy F
J Virol; 2003 Nov; 77(21):11546-54. PubMed ID: 14557640
[TBL] [Abstract][Full Text] [Related]
35. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
36. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
37. Rescue and propagation of fully retargeted oncolytic measles viruses.
Nakamura T; Peng KW; Harvey M; Greiner S; Lorimer IA; James CD; Russell SJ
Nat Biotechnol; 2005 Feb; 23(2):209-14. PubMed ID: 15685166
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
Ong HT; Timm MM; Greipp PR; Witzig TE; Dispenzieri A; Russell SJ; Peng KW
Exp Hematol; 2006 Jun; 34(6):713-20. PubMed ID: 16728275
[TBL] [Abstract][Full Text] [Related]
39. Measles virus.
Naim HY
Hum Vaccin Immunother; 2015; 11(1):21-6. PubMed ID: 25483511
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
